

48
11717AstraZeneca Pharmaceuticals LP
Docket No. PHM.70293/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Aiyar, J., *et al.*
Filed: December 10, 1998
Application No. 09/209,125

For: **HUMAN BRAIN-DERIVED TISSUE-SPECIFIC POTASSIUM CHANNEL**

Via FACSIMILE transmission to: 703-305-3704
Assistant Commissioner for Patents
Washington, DC 20231

Attention: Group Art Unit: 1646
Examiner: Nirmal S. Basi


Response to Restriction Requirement

Sir:

Applicants elect, without traverse, the subject matter of Invention II identified by the Examiner in an Office Action dated March 30, 2000, that is Claims 1-5 and 8-9 drawn to polynucleotides of Sequence ID No. 3 or Sequence ID No. 2, fragments thereof, vectors encoding, cells containing the aforementioned expression vectors and a method of production and recovery of the encoded protein of Sequence ID No. 3 from said cells, classified in class 536, subclass 23.1.

Applicants reserve the right to prosecute the subject matter of other inventions identified by the Examiner in this or future divisional or continuation applications.

Respectfully submitted,
AstraZeneca Pharmaceuticals LP



Kenneth F. Mitchell, Ph.D.
Attorney for Applicants
Reg. No. 42,007
Telephone: 302/886-7466

Dated: April 6, 2000